Printing the Future of Therapeutics in 3D
June 10-12, 2018
Peter Wall Institute for Advanced Studies
Vancouver, BC, Canada
FOSTERING RELATIONSHIPS AND DEVELOPING COLLABORATIONS
PFT3D is an exclusive roundtable event centered around facilitating discussion and collaboration on the development of commercially and clinically relevant life-saving tissues.
Aspect Biosystems and The University of British Columbia are proud to be co-organizing the second annual International Research Roundtable on Printing the Future of Therapeutics in 3D (PFT3D).
Last year’s inaugural event saw speakers from a wide variety of both academia and industry to discuss the amazing potential and applications of 3D bioprinting. This year, the roundtable will take place over 3 days and includes 20 speakers, covering four key areas:
Functional biofabricated tissues for disease modeling, therapeutic discovery, and regenerative medicine
Platform technologies to recreate biological function
Biomaterials for the development of functional tissues
An industry perspective on tissue engineering technologies
By the end of this meeting, we want you to leave with new inspirational ideas on groundbreaking projects, new partners and opportunities for collaboration, and a fresh perspective on the needs of industry and the translation of academic research.
In addition to our roundtable talks, there will be focused discussion sessions to address a variety of key challenges in our industry and facilitated networking sessions to stimulate interactions.
Welcome and Overview
Preclinical Applications & Therapeutic Development
Commercialization & Industry Relevance
The Social Impact of Bioprinting
Scientist, Drug & Target Discovery
Founder & CEO
Project Mgmt and Collaborations, Immune-Oncology Translational Development
Arnold & Porter Kaye Scholer LLP
Department of Materials Science & Engineering, University of Toronto
The Providence Airway Centre (PAC) at the Centre for Heart Lung Innovation (HLI) at St. Paul’s Hospital
Over the three days, 24 influential innovators from around the world will discuss the latest technological advances and challenges of bioprinting living human tissues, including the technical, ethical and societal issues of how bioprinting could lead to a future where drugs are developed without the use of animals, and where customized replacement organs are fabricated on-demand, instead of donated.
9:00-3:25pm: Closed Session
5:30-8:00pm: Café Scientifique
8:00-10:00pm: Dinner at Science World
Click on each day above for fully detailed schedule
VENUE & HOSTS
We are proud to be hosting this International Research Roundtable at the Peter Wall Institute for Advanced Studies on the beautiful University of British Columbia (UBC) campus in Vancouver, BC.
The Peter Wall Institute for Advanced Studies at the University of British Columbia (UBC) provides funding opportunities and an intellectual environment scholars are free to pursue the collaborative exchange of ideas beyond disciplinary boundaries.
The Institute’s goal is to stimulate creative, innovative research that makes important advances in knowledge, and to share or implement these ideas through ongoing community engagement. The Institute achieves this by supporting a highly collaborative environment at UBC where scholars have the opportunity to exchange ideas with national and international scholars, develop new thinking and engage in intellectual risk-taking.
The University of British Columbia is a global centre for research and teaching, consistently ranked among the 40 best universities in the world. Since 1915, UBC’s West Coast spirit has embraced innovation and challenged the status quo. Its entrepreneurial perspective encourages students, staff and faculty to challenge convention, lead discovery and explore new ways of learning. At UBC, bold thinking is given a place to develop into ideas that can change the world.
Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.